Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biodesix (BDSX) Cash & Equivalents (2019 - 2025)

Biodesix (BDSX) has disclosed Cash & Equivalents for 7 consecutive years, with $19.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash & Equivalents fell 27.65% year-over-year to $19.0 million, compared with a TTM value of $19.0 million through Dec 2025, down 27.65%, and an annual FY2025 reading of $19.0 million, down 27.65% over the prior year.
  • Cash & Equivalents was $19.0 million for Q4 2025 at Biodesix, up from $16.6 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $56.3 million in Q2 2021 and bottomed at $11.5 million in Q1 2024.
  • Average Cash & Equivalents over 5 years is $28.2 million, with a median of $24.4 million recorded in 2022.
  • The sharpest move saw Cash & Equivalents skyrocketed 660.52% in 2021, then plummeted 70.31% in 2022.
  • Year by year, Cash & Equivalents stood at $32.7 million in 2021, then surged by 31.72% to $43.1 million in 2022, then crashed by 39.0% to $26.3 million in 2023, then decreased by 0.15% to $26.2 million in 2024, then dropped by 27.65% to $19.0 million in 2025.
  • Business Quant data shows Cash & Equivalents for BDSX at $19.0 million in Q4 2025, $16.6 million in Q3 2025, and $20.7 million in Q2 2025.